The 6th WSPH Task Force on Hemodynamic Definitions and Clinical Classification recently proposed reducing the diagnostic mPAP threshold for pulmonary hypertension.
Despite substantial advances in therapeutic options for HFrEF, significant gaps remain in the use of guideline-directed medical therapy in these patients.
Mechanistic and outcomes studies are warranted to elucidate the lipid paradox and CVD risk in rheumatoid arthritis (RA).
Although pulmonary hypertension as a result of interstitial lung disease is linked to significant morbidity and mortality, there is no consensus regarding screening or management of the disease.
A substantial body of research points to a multifaceted link between depression and cardiovascular disease, with rates of depression being 3 times higher in patients with CAD.
Familial hypercholesterolemia is one of the most clinically relevant monogenic disorders contributing to the development of atherosclerotic cardiovascular disease.
Studies show increased rate of all types of dementia in patients with AF, with new data finding treatment of AF lowers risk for cognitive dysfunction.
Emerging evidence suggests that the extrapulmonary effects of pulmonary arterial hypertension may manifest in the form of vascular dysfunction in systemic circulation, metabolic/endocrine dysfunction, and skeletal and respiratory muscle dysfunction.
